G

Genomictree Inc
KOSDAQ:228760

Watchlist Manager
Genomictree Inc
KOSDAQ:228760
Watchlist
Price: 25 650 KRW -0.19% Market Closed
Market Cap: ₩625.3B

Net Margin

-233.3%
Current
Improving
by 82.2%
vs 3-y average of -315.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-233.3%
=
Net Income
₩-8.8B
/
Revenue
₩3.8B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-233.3%
=
Net Income
₩-8.8B
/
Revenue
₩3.8B

Peer Comparison

Country Company Market Cap Net
Margin
KR
Genomictree Inc
KOSDAQ:228760
617.2B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.8B USD
Loading...

Market Distribution

Lower than 96% of companies in Korea
Percentile
4th
Based on 2 632 companies
4th percentile
-233.3%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

Genomictree Inc
Glance View

Market Cap
625.3B KRW
Industry
Biotechnology

Genomictree, Inc. engages in the development and supply of diagnostic products for cancer screening and prognosis. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2016-07-19. The firm is involved in conducting of genomic analysis using microarrays and next generation sequencing analysis. In addition, the Company is conducting clinical trials for molecular diagnostic products. Molecular diagnostic products include cancer molecular diagnostic products and molecular genetic diagnostic products. Cancer molecular diagnostic products include molecular diagnostic products for colorectal cancer, bladder cancer, lung cancer, stomach cancer, cervical cancer. Molecular genetic diagnostic products include epidermal growth factor receptor (EGFR) mutation diagnosis, as well as human papilloma virus (HPV) diagnostic products.

Genomictree Inc Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-233.3%
=
Net Income
₩-8.8B
/
Revenue
₩3.8B
What is Genomictree Inc's current Net Margin?

The current Net Margin for Genomictree Inc is -233.3%, which is above its 3-year median of -315.5%.

How has Net Margin changed over time?

Over the last 3 years, Genomictree Inc’s Net Margin has decreased from -14.7% to -233.3%. During this period, it reached a low of -469.2% on Jun 30, 2024 and a high of -14.7% on Aug 30, 2022.

Back to Top